The deal RGS/Kyocera took longer than announced. RGS management might be cautious about saying too much re deals in the works. Their latest presentation was particularly light on this subject.
However, if Kyocera's recent partnerships are any indication, especially in the stem cells area, they have also supported their research partners with expansion in Europe through their network.
In other words, beyond the $27M upfront payments, the double digit royalties for incoming sales in Japan, the Kyocera partnership could accelerate RGS expansion in Europe, possibly in the US too. Most importantly, RGS was granted a US patent for Progenza in July 2018.
Onwards and upwards.
- Forums
- ASX - By Stock
- CMB
- Ann: Regeneus receives milestone payment from Kyocera
Ann: Regeneus receives milestone payment from Kyocera, page-22
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CMB (ASX) to my watchlist
(20min delay)
|
|||||
Last
46.0¢ |
Change
0.005(1.10%) |
Mkt cap ! $5.488M |
Open | High | Low | Value | Volume |
46.0¢ | 46.0¢ | 46.0¢ | $0 | 1 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1200 | 42.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.5¢ | 8 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1200 | 0.420 |
1 | 4314 | 0.410 |
1 | 400 | 0.400 |
1 | 6000 | 0.390 |
2 | 13292 | 0.380 |
Price($) | Vol. | No. |
---|---|---|
0.455 | 8 | 1 |
0.480 | 24 | 1 |
0.500 | 334 | 1 |
0.545 | 400 | 1 |
0.000 | 0 | 0 |
Last trade - 14.59pm 28/10/2024 (20 minute delay) ? |
Featured News
CMB (ASX) Chart |